Why the study?
Does the use of statins, ACE inhibitors, ARBs, or β-blockers reduce the risk of long-standing persistent AF in patients with newly diagnosed AF?
Does the use of statins, ACE inhibitors, ARBs, or β-blockers reduce the risk of long-standing persistent AF in patients with newly diagnosed AF?
Answers are grounded in this paper and cite their sources.
The use of statins, ACE inhibitors, ARBs, or β-blockers was not significantly associated with a reduced risk of developing long-standing persistent AF after an initial episode.
BACKGROUND: After an initial episode of atrial fibrillation (AF), patients may develop long-standing persistent or permanent AF. OBJECTIVE: We evaluated whether use of statins, angiotensin converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), or β-blockers is associated with lower risk of long-standing persistent AF after an initial AF episode. METHODS: We conducted a population-based inception cohort study of participants enrolled in Group Health, aged 30 to 84 years, with newly diagnosed AF in 2001-2004. We included only participants whose initial AF episode terminated within 6 months of onset. We ascertained the primary outcome of long-standing persistent AF from medical records, electrocardiograms, and administrative data. We determined time-varying medication use from Group Health pharmacy data. RESULTS: Among 1317 participants with incident AF, 304 developed long-standing persistent AF. Our study suggests that current statin use versus never use may be associated with lower risk for long-standing persistent AF. However, the association was not statistically significant when adjusted for age, sex, cardiovascular risk factors, and current use of antiarrhythmic medication (hazard ratio [HR] = 0.77; 95% CI = 0.57, 1.03). In lagged analyses intended to reduce healthy user bias, current statin use 1 year prior versus never use 1 year prior was not associated with risk for long-standing persistent AF (HR = 0.91; 95% CI = 0.67, 1.24). ACE inhibitor, ARB, and β-blocker use were not associated with risk for long-standing persistent AF. CONCLUSIONS: Current statin use may confer protection that wanes after discontinuing use. Alternatively, healthy user bias or chance may explain the association. The association of statin use with long-standing persistent AF warrants further investigation.
No takes yet. Share an insight, caveat, or question.
Thacker et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: